Back to top
more

Envista (NVST)

(Real Time Quote from BATS)

$16.46 USD

16.46
1,741,083

-0.04 (-0.24%)

Updated Aug 9, 2024 01:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Charles River (CRL) Advances in Gene Therapy With Vigene Buyout

by Zacks Equity Research

The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.

Here's Why You Should Buy National Vision (EYE) Stock Now

by Zacks Equity Research

Investors remain optimistic about National Vision (EYE) on increased eyeglass comparable demand and encouraging 2021 strategies.

Medtronic (MDT) Diabetes Arm Grows With Favorable InPen Data

by Zacks Equity Research

Medtronic's (MDT) InPen is a FDA as well as CE Mark-cleared smart insulin pen available for patients who require multiple daily injections.

SmileDirectClub (SDC) Reels Under Cyber Attack, Pandemic Woes

by Zacks Equity Research

SmileDirectClub (SDC) apprehends systems outage to have an adverse impact on its second-quarter revenues to the tune of approximately $10-$15 million.

Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.

Globus Medical (GMED) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) owing to significant trend improvement and the company's focus on product development.

Boston Scientific (BSX) Eyeing Remaining 73% Farapulse Stake

by Zacks Equity Research

Boston Scientific (BSX) currently holds an equity stake of roughly 27%.

Medtronic (MDT) Global Market Share Rises Amid Pandemic Blues

by Zacks Equity Research

Most of Medtronic (MDT) end markets are gradually returning to near-normal pre-COVID growth.

OPKO Health (OPK) and Nicoya Sign RAYALDEE Deal

by Zacks Equity Research

OPKO Health's (OPK) subsidiary EirGen Pharma to develop and commercialize RAYALDEE in Greater China in collaboration with an affiliate of Nicoya Therapeutics.

NEOGEN (NEOG) Enhances Aquaculture Genotyping With New Pact

by Zacks Equity Research

NEOGEN (NEOG) together with CAT can enable members of the aquaculture sector to make more informed breeding decisions.

Medtronic (MDT) Reports First Surgery With Hugo RAS System (Revised)

by Zacks Equity Research

Medtronic (MDT) to begin patient registry for the Hugo RAS system following first successful patient procedure at Clinica Santa Maria in Chile.

LabCorp (LH), Molecular Loop Team Up for COVID-19 Test Research

by Zacks Equity Research

The SARS-CoV-2 Research Sequencing Panel will help LabCorp (LH) sequence thousands of complete coronavirus genomes each week from positive patient samples.

Hologic (HOLX) Gets European Nod for Aptima CMV Quant Assay

by Zacks Equity Research

Hologic's (HOLX) Aptima CMV Quant assay is intended to help in the diagnosis and management of solid-organ transplant patients and hematopoietic stem cell transplant patients.

Medtronic (MDT) Reports First Surgery With Hugo RAS System

by Zacks Equity Research

Medtronic (MDT) to begin patient registry for the Hugo RAS system following first successful patient procedure at Clinica Santa Maria in Chile.

Quest Diagnostics (DGX) Unveils Corporate Responsibility Report

by Zacks Equity Research

Per Quest Diagnostics' (DGX) 2020 Corporate Responsibility Report, it has expanded COVID-19 capacity throughout the year, performing 30 million COVID-19 molecular tests and serology tests.

Medtronic (MDT) Gets Expanded FDA Nod for Cryoablation Catheters

by Zacks Equity Research

Medtronic's (MDT) Cardiac Cryoablation Catheters offer safe and effective substitute to antiarrhythmic drug therapy for the prevention of atrial arrythmia recurrence.

Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and bullish 2021 earnings guidance.

Illumina's (ILMN) NovaSeq Adoption Aids, Margin Woe Stays

by Zacks Equity Research

Illumina (ILMN) derives benefits from the cascading effect of the ACOG guidance on increasing coverage of NIPT for all pregnancies.

Hologic (HOLX) to Beat Post-COVID Woes With Mobidiag Buyout

by Zacks Equity Research

Hologic (HOLX) management believes that Mobidiag has created a differentiated platform that deals with many of the historical challenges faced in multiplexed point-of-care molecular testing.

NEOGEN's (NEOG) Soleris Test to Serve the Cannabis Industry

by Zacks Equity Research

NEOGEN's (NEOG) Soleris Direct Yeast and Mold test is approved by the AOAC Institute to identify yeasts and molds in dried cannabis flower.

    Abbott's (ABT) Base Business Recovers, Lowered View Concerns

    by Zacks Equity Research

    According to Abbott (ABT), significant reductions in the number of COVID-19 cases in the United States and other major developed countries to hamper demand for COVID-19 testing in 2021.

      ResMed (RMD) Hits a New 52-Week High: What's Driving It?

      by Zacks Equity Research

      Investors are optimistic about ResMed (RMD) on solid digital health growth potential along with rising demand for masks and other accessories.

      Thermo Fisher's (TMO) New Launch Boosts Preclinical Development

      by Zacks Equity Research

      Thermo Fisher's (TMO) enhanced Quick to Clinic solution provides balance of speed and quality to accelerate and advance DNA to Investigational New Drug in as less as 13 months.

      CVS Health (CVS) Digital Tools Gain Steam Amid COVID-19 Crisis

      by Zacks Equity Research

      CVS Health's (CVS) consumer-centric digital strategy is more relevant in the current environment as people are increasingly using technology while staying indoors.

      Bruker (BRKR) Updates 2021 Outlook, Issues Medium-Term View

      by Zacks Equity Research

      Bruker (BRKR) updates 2021 financial guidance encouraged by solid business growth and high-growth opportunities.